A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Clinical trial NCT07703657 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07703657
- Sponsor
- Yang Donglin
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-09
- Primary completion
- 2027-07-09
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.